ATOS - Company ID 0001488039
The table below shows ATOSSA THERAPEUTICS, INC.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$29.76M | -$21.03M | -$20.94M | -$20.76M | -$16.47M | -$11.57M |
| Capital expenditure | $23.00K | $19.00K | $14.00K | $27.00K | $9.00K | $9.00K |
| Investing cash flow | -$23.00K | -$19.00K | -$14.00K | -$4.73M | -$9.00K | -$9.00K |
| Dividends paid | - | - | - | - |
ATOSSA THERAPEUTICS, INC. reported operating cash flow of -$29.76M for fiscal year 2025. That is down 41.5% from -$21.03M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$5.37M (FY 2016) to -$29.76M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | $0.00 | $1.48M | $0.00 | - | - |
| Financing cash flow | $0.00 | $3.67M | -$1.48M | $0.00 | $113.30M | $38.55M |